## Implementing a timed HPB cancer diagnostic pathway. Pancreatic, liver, bile duct and gall bladder.

### Audit tool

This tool can be used to undertake a baseline audit of services being delivered and whether sufficient capacity is in place to routinely deliver, identify areas for improvement, select measurements for improvement, and conduct re-audits as part of continuous improvement. Patient experience measures should also be considered as part of auditing and improvement.

Table 1: Jaundice, pancreatic, extrahepatic cholangiocarcinoma and gall bladder

| **Day** | **Pathway step** | **Service in place?** | **Capacity in place?** |
| --- | --- | --- | --- |
| 0 | GP referral and locally agreed minimum dataset |  |  |
| Primary care patient information resources provided, co-developed with patients |  |  |
| 5 | Straight to CT and bloods |  |  |
| Commence PERT if required |  |  |
| Secondary care patient information resources and support provided, co-developed with patients |  |  |
| 8 | Clinical assessment of CT results, using [PACT-UK radiology reporting pro-forma](https://www.bsgar.org/media/PACT-UK%20(plain%20text%20version)%20Aug21.docx) if required |  |  |
| Booking of MRI, MRCP, PET-CT, laparoscopy / laparoscopic US as required |  |  |
| 10 | MDT for review and planning of diagnostic tests and potential treatment options |  |  |
| 16 | MRI or MRCP carried out |  |  |
| PET-CT or laparoscopy / laparoscopic ultrasound |  |  |
| ERCP or EUS guided FNA Biopsy |  |  |
| Cancer ruled out or diagnosis confirmed with patient, further support and signposting provided |  |  |
| 21 | Treatment and care options discussed at multi-disciplinary outpatient clinic |  |  |

Table 2: Hepatocellular carcinoma and intrahepatic cholangiocarcinoma

|  |  |  |  |
| --- | --- | --- | --- |
| **Day** | **Pathway step** | **Service in place?** | **Capacity in place?** |
| 0 | GP referral and locally agreed minimum dataset |  |  |
| Primary Care patient information resources provided, co-developed with patients |  |  |
| 5 | Straight to Ultrasound and bloods |  |  |
| Multiphase CT or Contrast MRI |  |  |
| Secondary care patient information resources and support provided, co-developed with patients |  |  |
| 8 | Clinical assessment of CT or MRI results |  |  |
| Booking of Multiphase CT, PET-CT or Contrast MRI as required |  |  |
| 10 | MDT for review and planning of diagnostic tests and potential treatment options |  |  |
| 16 | Contrast MRI carried out (if not already carried out by day 3) |  |  |
| Multiphase CT (if not already carried out by day 3), or PET-CT carried out |  |  |
| Persutaneous Biopsy, EUS guided FNA Biopsy, and/or ERCP and Cholangioscopy |  |  |
| Cancer ruled out or diagnosis confirmed with patient, further support and signposting provided |  |  |
| 21 | Treatment and care options discussed at multi-disciplinary outpatient clinic |  |  |